Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The biotech drug market

In recent years, biotech has claimed an increasing share of novel treatments approved by the US Food and Drug Administration; that trend will shift this year. Although recombinant drugs account for more than one-third of candidates in discovery, the share dwindles along the pipeline. Currently, only 8 out of 100 new drug or biologic applications are for biotech treatments. Only eight biotech drugs on the market have sales over $1 billion, but analysts suggest several late-stage products could turn into blockbusters.

Credit: Source: BioPharm Insight
Credit: Source: BioPharm Insight
Credit: Source: Food and Drug Administration, Center for Biologics Evaluation and Research
Credit: Source: SG Cowen
Credit: Source: IMS Health, Credit Suisse First Boston
Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lawrence, S. The biotech drug market. Nat Biotechnol 22, 1496 (2004). https://doi.org/10.1038/nbt1204-1496

Download citation

Search

Quick links